{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:10:59Z","timestamp":1792300259291,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":2562,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1038\/ki.2008.522","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T13:38:12Z","timestamp":1227706692000},"page":"S29-S32","source":"Crossref","is-referenced-by-count":34,"special_numbering":"S111","title":["Renal manifestations in Fabry disease and therapeutic options"],"prefix":"10.1016","volume":"74","author":[{"given":"Roser","family":"Torra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2008.522_bb0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2008.522_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.522_bb0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1038\/ki.2008.522_bb0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J Med Genet"},{"key":"10.1038\/ki.2008.522_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"key":"10.1038\/ki.2008.522_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0954-6820.1979.tb13458.x","article-title":"Inactivation of one of the X chromosomes in females is a biological phenomenon of clinical importance","volume":"206","author":"Berg","year":"1979","journal-title":"Acta Med Scand"},{"key":"10.1038\/ki.2008.522_bb0040","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J Mol Med"},{"key":"10.1038\/ki.2008.522_bb0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1038\/ki.2008.522_bb0050","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 7","key":"10.1038\/ki.2008.522_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","article-title":"Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry","volume":"11","author":"Tsakiris","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.522_bb0060","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u2018renal variant\u2019 phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.522_bb0065","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","article-title":"Results of a nationwide screening for Anderson-Fabry disease among dialysis patients","volume":"15","author":"Kotanko","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 2","key":"10.1038\/ki.2008.522_bb0070","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease","volume":"13","author":"Branton","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.522_bb0075","first-page":"310","article-title":"Renal involvement in Anderson-Fabry disease","volume":"16","author":"Sessa","year":"2003","journal-title":"J Nephrol"},{"key":"10.1038\/ki.2008.522_bb0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ncpneph0806","article-title":"Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults","volume":"4","author":"Ortiz","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1038\/ki.2008.522_bb0085","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1126\/science.172.3979.174","article-title":"Fabry's disease: antenatal detection","volume":"172","author":"Brady","year":"1971","journal-title":"Science"},{"key":"10.1038\/ki.2008.522_bb0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","article-title":"Manifestations of Fabry disease in placental tissue","volume":"29","author":"Vedder","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/ki.2008.522_bb0095","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"Tondel","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.522_bb0100","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1523-1755.2004.00846.x","article-title":"Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease","volume":"66","author":"Ries","year":"2004","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"10.1038\/ki.2008.522_bb0105","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","article-title":"Renal pathology in Fabry disease","volume":"13","author":"Alroy","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.522_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.522_bb0115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/ki.2008.522_bb0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1038\/ki.2008.522_bb0125","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur J Pediatr"},{"key":"10.1038\/ki.2008.522_bb0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00041552-200503000-00002","article-title":"Fabry disease: diagnosis and management, with emphasis on the renal manifestations","volume":"14","author":"Warnock","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1038\/ki.2008.522_bb0135","doi-asserted-by":"crossref","first-page":"445","DOI":"10.5414\/CNP69445","article-title":"Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy","volume":"69","author":"Torra","year":"2008","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2008.522_bb0140","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/sj.ki.5002677","article-title":"Fabry disease: an under recognized cause of proteinuria","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.522_bb0145","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1038\/ki.2008.522_bb0150","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.522_bb0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.522_bb0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2008.522_bb0165","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.522_bb0170","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.522_bb0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1038\/ki.2008.522_bb0180","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1038\/ki.2008.522_bb0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1038\/ki.2008.522_bb0190","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ndt\/18.1.33","article-title":"Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function","volume":"18","author":"De","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.522_bb0195","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry's disease","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"key":"10.1038\/ki.2008.522_bb0200","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","article-title":"Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study","volume":"65","author":"Mignani","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.522_bb0205","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1523-1755.2004.00883.x","article-title":"Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease","volume":"66","author":"Kosch","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.522_bb0210","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1523-1755.2004.00440.x","article-title":"Fabry disease: kidney involvement and enzyme replacement therapy","volume":"65","author":"Siamopoulos","year":"2004","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815532389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815532389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T18:55:18Z","timestamp":1557946518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815532389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":41,"alternative-id":["S0085253815532389"],"URL":"https:\/\/doi.org\/10.1038\/ki.2008.522","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}